McDonnell Boehnen Hulbert & Berghoff LLP partner Dr. Kevin E. Noonan is quoted in a January 30, 2017 edition of Bloomberg BNA’s Life Sciences Law & Industry Report in an article entitled, “Do Biopharmas Abuse the Orphan Drug Act? Debate Resurfaces.” New claims that biopharma companies abuse federal incentives to develop drugs for rare diseases have rekindled the debate, but the FDA and other stakeholders still say the Orphan Drug Act program is a success. View the article